INDICATIONS & DOSING
SIMPONI® is indicated for the treatment of:
• Moderately to severely active RA in adults, in combination with methotrexate (MTX)
• Active psoriatic arthritis (PsA) in adults, alone or in combination with MTX
• Active ankylosing spondylitis (AS) in adults
SIMPONI® is administered by 50-mg subcutaneous (SC) injection once a month.
SIMPONI® is intended for use under the guidance and supervision of a physician.
Patients may self-inject with SIMPONI® after physician approval and proper training.
SIMPONI® is indicated in adults with moderately to severely active ulcerative colitis (UC) for inducing and maintaining clinical response, improving endoscopic appearance of the mucosa during induction, inducing clinical remission, and achieving and sustaining clinical remission in induction responders who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine.
SIMPONI® is given as a 100-mg subcutaneous (SC) injection every 4 weeks after 3 starter injections.
SIMPONI® is intended for use under the guidance and supervision of a physician.
Patients may self-inject SIMPONI® after physician approval and proper training.